Chester County News and Community Website
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has reported new clinical evidence suggesting its atrioventricular interval modulation (AVIM) therapy may significantly improve heart function in patients with …
Orchestra BioMed Study Shows AVIM Therapy Could Transform Care for Hypertensive Heart Disease Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) reported second-quarter 2025 results alongside a series of major financing and regulatory developments that position the company to advance its …
Orchestra BioMed Secures $111M to Advance Late-Stage Cardiac Therapies, Hits Multiple FDA Milestones Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced a major expansion to the patient eligibility criteria for its ongoing BACKBEAT study, aimed at evaluating the effectiveness of its …
FDA Greenlights Broader Patient Access for AVIM Therapy Trial in Pacemaker Patients Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced $70 million in new capital commitments from Ligand Pharmaceuticals (Nasdaq: LGND) and Medtronic (NYSE: MDT), bolstering its efforts to …
Orchestra BioMed Secures $70 Million in Strategic Investments to Advance Cardiology Pipeline Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has presented key clinical insights into its atrioventricular interval modulation (AVIM) therapy for high-risk hypertension during the Congenital, Structural, and …
Orchestra BioMed Highlights AVIM Therapy’s Potential at CSI 2025 Meeting Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has announced its financial results for the first quarter ended March 31, 2025, alongside significant regulatory and clinical milestones that …
Orchestra BioMed Reports Q1 2025 Financial Results and Advances Key Clinical Programs Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has announced significant advancements in the intellectual property backing its AVIM (Atrioventricular Interval Modulation) therapy pipeline. Over the past year, …
Orchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough Designation Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has received FDA approval to move forward with its Virtue Trial, a pivotal clinical study designed to evaluate its next-generation …
Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has announced its participation in the upcoming Jefferies Global Healthcare Conference, which will be held in New York, NY, on …
Orchestra BioMed to Present at Jefferies Global Healthcare Conference Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) will host a satellite symposium at the Heart Rhythm Society (HRS) 2025 Annual Meeting in San Diego to spotlight its …
Orchestra BioMed to Highlight Advancements in Cardiac Therapy at HRS 2025 Read More